Comparing ranibizumab with bevacizumab

Ophthalmology

Volumn 118, Issue 3, 2011, Pages

  Biswas, Partha ^a   Sengupta, Subhrangshu ^a   Choudhary, Ruby ^a   Home, Subhankar ^a   Paul, Ajoy ^a   Sinha, Sourav ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 79952266260     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2010.10.027     Document Type: Letter

References (3)

1. G. Landa, W. Amde, and V. Doshi Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration Ophthalmologica 223 2009 370 375
2. K.E. Stepien, P.J. Rosenfeld, and C.A. Puliafito Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration Retina 29 2009 1067 1073
3. T.S. Chang, G. Kokame, and R. Casey Short-term effectiveness of intravitreal bevacizumab versus ranibizumab 20 injections for patients with neovascular age-related macular degeneration Retina 29 2009 1235 1241